Raphi Levy Sells 2,871 Shares of Alpha Tau Medical (NASDAQ:DRTS) Stock

Key Points

• Alpha Tau Medical CFO Raphi Levy sold 2,871 shares at an average price of $15, generating $43,065. The Rule 10b5-1 transaction reduced his direct holdings by 3.09% to 90,180 shares, following several earlier sales.
• DRTS shares rose 0.3% to $14.75 and are near their 52-week high of $15.02, with the stock up substantially from its $3.18 low. However, the company reported a quarterly EPS loss of $0.50, missing the $0.14 consensus estimate.
• Analyst sentiment remains broadly positive, with an overall “Moderate Buy” rating and five Buy recommendations, though the average price target is $12.80. Institutional ownership remains limited at 2.65%.

Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report) CFO Raphi Levy sold 2,871 shares of Alpha Tau Medical stock in a transaction on Friday, August 21st. The stock was sold at an average price of $15.00, for a total transaction of $43,065.00. Following the sale, the chief financial officer directly owned 90,180 shares in the company, valued at $1,352,700. This trade represents a 3.09% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Raphi Levy also recently made the following trade(s):

• On Tuesday, August 11th, Raphi Levy sold 17,730 shares of Alpha Tau Medical stock. The shares were sold at an average price of $14.00, for a total transaction of $248,220.00.
• On Monday, July 6th, Raphi Levy sold 2,270 shares of Alpha Tau Medical stock. The shares were sold at an average price of $14.00, for a total value of $31,780.00.
• On Thursday, July 2nd, Raphi Levy sold 17,873 shares of Alpha Tau Medical stock. The stock was sold at an average price of $13.00, for a total value of $232,349.00.
• On Wednesday, July 1st, Raphi Levy sold 2,127 shares of Alpha Tau Medical stock. The stock was sold at an average price of $13.02, for a total value of $27,693.54.
• On Tuesday, June 30th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The shares were sold at an average price of $12.00, for a total value of $240,000.00.
• On Thursday, June 25th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The shares were sold at an average price of $11.00, for a total value of $220,000.00.
• On Tuesday, June 23rd, Raphi Levy sold 17,500 shares of Alpha Tau Medical stock. The shares were sold at an average price of $9.55, for a total value of $167,125.00.
• On Wednesday, June 3rd, Raphi Levy sold 32,500 shares of Alpha Tau Medical stock. The shares were sold at an average price of $10.83, for a total value of $351,975.00.

Alpha Tau Medical Stock Up 0.3%

Shares of Alpha Tau Medical stock traded up $0.05 on Tuesday, hitting $14.75. 116,827 shares of the company's stock traded hands, compared to its average volume of 586,023. Alpha Tau Medical Ltd. has a 52-week low of $3.18 and a 52-week high of $15.02. The company has a quick ratio of 7.79, a current ratio of 11.09 and a debt-to-equity ratio of 0.15. The stock has a market cap of $1.33 billion, a P/E ratio of -14.12 and a beta of 1.17. The firm's 50-day moving average is $12.53 and its 200 day moving average is $9.68.

Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.36). The company had revenue of $0.10 million for the quarter, compared to analyst estimates of $0.14 million. Equities analysts anticipate that Alpha Tau Medical Ltd. will post -0.92 earnings per share for the current year.

Wall Street Analyst Weigh In

DRTS has been the topic of a number of recent analyst reports. HC Wainwright upped their target price on shares of Alpha Tau Medical from $15.00 to $16.00 and gave the company a "buy" rating in a research note on Tuesday, August 11th. Benchmark reissued a "buy" rating on shares of Alpha Tau Medical in a report on Thursday, July 23rd. Zacks Research upgraded Alpha Tau Medical from a "strong sell" rating to a "hold" rating in a research note on Monday, August 3rd. LADENBURG THALM/SH SH upped their price objective on Alpha Tau Medical from $12.00 to $14.00 and gave the company a "buy" rating in a research note on Tuesday, May 12th. Finally, Barclays increased their target price on Alpha Tau Medical from $15.00 to $17.00 and gave the stock an "overweight" rating in a report on Thursday, June 4th. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $12.80.

Institutional Investors Weigh In On Alpha Tau Medical

Institutional investors have recently modified their holdings of the business. Trifecta Capital Advisors LLC bought a new position in Alpha Tau Medical in the fourth quarter worth about $48,000. Everhart Financial Group Inc. bought a new position in shares of Alpha Tau Medical during the second quarter valued at approximately $126,000. Envestnet Asset Management Inc. acquired a new stake in shares of Alpha Tau Medical during the 3rd quarter worth approximately $62,000. Principal Financial Group Inc. acquired a new stake in shares of Alpha Tau Medical during the 1st quarter worth approximately $132,000. Finally, Bank of America Corp DE lifted its holdings in shares of Alpha Tau Medical by 2,779.1% in the 3rd quarter. Bank of America Corp DE now owns 22,457 shares of the company's stock worth $101,000 after purchasing an additional 21,677 shares during the last quarter. Institutional investors own 2.65% of the company's stock.

About Alpha Tau Medical

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company's core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company's lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source